-
胰腺属于腹膜后器官, 胰腺癌早期没有特异性的症状, 出现症状时多数已属于晚期。胰腺癌主要指胰外分泌腺腺癌, 是胰腺恶性肿瘤中最常见的一种, 占消化道恶性肿瘤的8%~10%、常见恶性肿瘤的1%~2%。近年来, 胰腺癌的发生率呈明显上升趋势。近20年内, 上海胰腺癌的发病率增加了4倍[1]。目前, 胰腺癌的手术治疗还只限于I期或者是II期中T2N0M0的患者, 多数患者就诊时已经丧失了手术的最佳时机, 所以早期诊断具有重要意义。PET-CT是功能与解剖的融合图像, 既能重点反映肿瘤组织的代谢和增生情况, 又能提示肿瘤组织与其周围结构的毗邻关系, 在胰腺癌诊断、分期、疗效评价和判断预后等方面具有其独特的价值。
18F-FDG PET-CT在胰腺癌诊治中的应用
18F-FDG PET-CT for the clinical application of pancreatic cancer
-
摘要: 胰腺癌是一种常见的消化系统恶性肿瘤,其预后差、5年生存率低,早期诊断具有重要的意义。18F-FDG PET-CT集功能影像与解剖成像于一体,能够反映肿瘤组织的代谢和细胞增生水平,以及肿瘤组织与周围结构的毗邻关系。因此,其在胰腺癌的诊断、分期、疗效评价及预后的判断等方面具有较为明显的优势。该文综述了18F-FDG PET-CT在胰腺癌诊治中的应用价值。
-
关键词:
- 胰腺肿瘤 /
- 正电子发射断层摄影术 /
- 体层摄影术, X线计算机 /
- 氟脱氧葡萄糖F18
Abstract: Pancreatic cancer is one of the common malignant tumors in the digestive system, which has poor prognosis and low of 5-years survival rate, so for the early diagnosis of pancreatic cancer is extremely important.18F-FDG PET-CT imaging system combines the functional and anatomical imaging in one, it not only to reflect the metabolism of tumor tissue, hyperplasia of the level, but also to reflect the anatomy of the tumor and surrounding tissue relationship.18F-FDG PET-CT has its advantages for the diagnosis of pancreatic cancer, differential diagnosis, staging and prognosis.This review focuses on18F-FDG PET-CT for the clinicalapplication of pancreatic cancer. -
[1] 陈灏珠, 林果为. 实用内科学. 13版. 北京: 人民卫生出版社, 2009.
[2] Delbeke D, Martin WM. PET and PET/CT for pancreatic malignanies. Surg Oncol Clin N Am, 2010, 19(2): 235-254. doi: 10.1016/j.soc.2009.11.005 [3] Dewitt J, Devereaux BM, Lehman GA, et al. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol, 2006, 4(6): 717-725. doi: 10.1016/j.cgh.2006.02.020 [4] Mertz HR, Sechopoulos P, Delbeke D, et al. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc, 2000, 52(3): 367-371. doi: 10.1067/mge.2000.107727 [5] Vargas R, Nino-Murcia M, Trueblood W, et al. MDCT in pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol, 2004, 182(2): 419-425. doi: 10.2214/ajr.182.2.1820419 [6] Park SS, Lee KT, Lee KH, et al. Diagnostic usefulness of PET/CT for pancreatic malignancy. Korean J Gastroenterol, 2009, 54(4): 235-242. doi: 10.4166/kjg.2009.54.4.235 [7] Lemke AJ, Niehues SM, Hosten N, et al. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions—a prospective study with 104 patients. J Nucl Med, 2004, 45(8): 1279-1286. [8] Sperti C, Pasquali C, Decet G, et al. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg, 2005, 9(1): 22-28. doi: 10.1016/j.gassur.2004.10.002 [9] Sperti C, Bissoli S, Pasquali C, et al. 18-Fluorodeoxy glucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg, 2007, 246(6): 932-937. doi: 10.1097/SLA.0b013e31815c2a29 [10] Nishiyama Y, Yamamoto Y, Yokoe K, et al. Contribution of whole body FDG PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med, 2005, 19(6): 491-497. doi: 10.1007/BF02985577 [11] Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods(US, CT, MR imaging, PET): a meta-analysis. 2002, 224(3): 748-756. [12] Farma JM, Santillan AA. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol, 2008, 15(9): 2465-2471. doi: 10.1245/s10434-008-9992-0 [13] Kysucan J, Lovecek M, Klos D, et al. Benefit of PET/CT in the preoperative staging in pancreatic carcinomas. Rozhl Chir, 2010, 89(7): 433-440. [14] Saif MW, Cornfeld D, Modarresifar H, et al. 18F-FDG positron emission tomography CT(FDG PET-CT)in the management of pancreatic cancer: Initial experience in 12 patients. J Gastrointestin Liver Dis, 2008, 17(2): 173-178. [15] Topkan E, Yavuz AA, Avdin M, et al. Comparison of CT and PETCT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Cancer Res, 2008, 27(1): 41. doi: 10.1186/1756-9966-27-41 [16] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3): 205-216. doi: 10.1093/jnci/92.3.205 [17] Heinrich S, Schäfer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg, 2008, 248(6): 1014-1022. doi: 10.1097/SLA.0b013e318190a6da [18] Choi M, Heilbrun LK, Venkatramanamoorthy R, et al. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol, 2010, 33(3): 257-261. doi: 10.1097/COC.0b013e3181a76a0b [19] Schellenberg D, Quon A, Minn AY, et al. 18 Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys, 2010, 77(5): 1420-1425. doi: 10.1016/j.ijrobp.2009.06.049 [20] Lee TY, Kim MH. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol, 2009, 193(2): 343-348. doi: 10.2214/AJR.08.2297 [21] 王欣, 于丽娟. 18F-FDG PET/CT综合分析法在胰腺癌诊断中的价值. 中国医学影像技术, 2007, 23(11): 1709-1712. doi: 10.3321/j.issn:1003-3289.2007.11.036
[22] Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. EurJ Nucl Med, 1997, 24(6): 678-682. [23] Samnick S, Romeike BF, Kubuschok B, et al. p-[123I]iodo-L-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma. EurJ Nucl Med Mol Imaging, 2004, 31(4): 532-541. doi: 10.1007/s00259-003-1445-1 [24] Flores LG, Bertolini S, Yeh HH, et al. Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using[18F]fluoroethyl-deoxy lactose PE T/CT. PLoS ONE, 2009, 4(11): e7977. doi: 10.1371/journal.pone.0007977
计量
- 文章访问数: 1769
- HTML全文浏览量: 585
- PDF下载量: 3